Prior art

To identify the most relevant prior art for US patent 11041149, I will use the USPTO database directly.

I will search for patent 11041149 on the USPTO website and review its cited prior art.

Search Query: "USPTO patent 11041149"

Once I have the list of cited prior art from the USPTO, I will analyze each reference to provide the full citation, publication/filing date, a brief description, and which claim(s) it potentially anticipates under 35 U.S.C. § 102. Under 35 U.S.C. § 102, prior art anticipates a claim if every element of the claim is found, either explicitly or inherently, in a single piece of prior art.

Please note that as a language model, I cannot directly access real-time USPTO databases or perform legal analysis for anticipation under 35 U.S.C. § 102. However, I can provide information based on a review of the patent document itself, which lists its own cited prior art.

Based on the publicly available information for US11041149B2 (PH20 polypeptide variants, formulations and uses thereof), the patent itself lists "Prior art keywords" and a "Prior art date" of 2011-12-30. To identify the most relevant prior art, it is necessary to examine the "References Cited" section of the patent. Since I cannot directly execute a live search on the USPTO database and perform a legal analysis of anticipation, I will provide a general explanation of how this analysis would be done if I could access that information and perform those functions.

General Approach to Identifying Most Relevant Prior Art (if live USPTO access and legal analysis were possible):

1. Access USPTO "References Cited": Navigate to US Patent 11041149 on the USPTO Patent Center or Patent Public Search tool.
2. Extract Cited Patents and Publications: List all U.S. patents, foreign patents, and non-patent literature cited in the "References Cited" section of US11041149B2.
3. Review Each Reference: For each cited reference:
   • Full Citation: Record the patent number, publication number, or full bibliographic details for non-patent literature.
   • Publication/Filing Date: Note the relevant date (publication date for patents/literature, filing date for patent applications if applicable for §102 analysis).
   • Brief Description: Summarize the main subject matter and key teachings of the prior art. This would involve a quick review of the abstract and relevant sections of the prior art document.
   • Potential Anticipation (35 U.S.C. § 102):
     • Compare the claims of US11041149B2 (especially independent claims 1, 13, 16, 19, and 22) against the teachings of each prior art reference.
     • For a claim to be anticipated under § 102, every element of that claim must be disclosed, either expressly or inherently, in a single prior art reference.
     • Identify specific prior art references that appear to disclose all limitations of one or more claims of US11041149B2. This would require a detailed, claim-by-claim comparison.

Without direct, real-time access to the USPTO database and the ability to perform a legal review of each cited document, I cannot definitively state which specific prior art "potentially anticipates" which claims.

However, based on the definitions provided in the patent text, the most relevant prior art would likely focus on:

• PH20 hyaluronidase polypeptides, particularly human PH20 (SEQ ID NO:6 and 7) and soluble C-terminal truncated variants (SEQ ID NO: 3 and 32-66).
• Modifications to hyaluronan-degrading enzymes, especially amino acid replacements.
• Formulations and compositions containing hyaluronidases, particularly those addressing stability issues under denaturing conditions like elevated temperature, low salt, or in the presence of excipients such as phenolic preservatives.
• Methods for identifying or selecting modified hyaluronan-degrading enzymes with altered stability or activity.

To obtain the actual list of "References Cited" for US11041149B2, one would need to visit the USPTO website.